The hidden Niemann-Pick type C patient : clinical niches for a rare inherited metabolic disease
| dc.contributor.author | Hendriksz, Christian J. | |
| dc.contributor.author | Anheim, Mathieu | |
| dc.contributor.author | Bauer, Peter | |
| dc.contributor.author | Bonnot, Olivier | |
| dc.contributor.author | Chakrapani, Anupam | |
| dc.contributor.author | Corvol, Jean-Christophe | |
| dc.contributor.author | De Koning, Tomas J. | |
| dc.contributor.author | Degtyareva, Anna | |
| dc.contributor.author | Dionisi-Vici, Carlo | |
| dc.contributor.author | Doss, Sarah | |
| dc.contributor.author | Duning, Thomas | |
| dc.contributor.author | Giunti, Paola | |
| dc.contributor.author | Iodice, Rosa | |
| dc.contributor.author | Johnston, Tracy | |
| dc.contributor.author | Kelly, Dierdre | |
| dc.contributor.author | Klünemann, Hans-Hermann | |
| dc.contributor.author | Lorenzl, Stefan | |
| dc.contributor.author | Padovani, Alessandro | |
| dc.contributor.author | Pocovi, Miguel | |
| dc.contributor.author | Synofzik, Matthis | |
| dc.contributor.author | Terblanche, Alta J. | |
| dc.contributor.author | Then Bergh, Florian | |
| dc.contributor.author | Topçu, Meral | |
| dc.contributor.author | Tranchant, Christine | |
| dc.contributor.author | Walterfang, Mark | |
| dc.contributor.author | Velten, Christian E. | |
| dc.contributor.author | Kolb, Stefan A. | |
| dc.date.accessioned | 2018-03-01T07:31:05Z | |
| dc.date.issued | 2017-03 | |
| dc.description.abstract | BACKGROUND : Niemann-Pick disease type C (NP-C) is a rare, inherited neurodegenerative disease of impaired intracellular lipid trafficking. Clinical symptoms are highly heterogeneous, including neurological, visceral, or psychiatric manifestations. The incidence of NP-C is under-estimated due to under-recognition or misdiagnosis across a wide range of medical fields. New screening and diagnostic methods provide an opportunity to improve detection of unrecognized cases in clinical sub-populations associated with a higher risk of NP-C. Patients in these at-risk groups (“clinical niches”) have symptoms that are potentially related to NP-C, but go unrecognized due to other, more prevalent clinical features, and lack of awareness regarding underlying metabolic causes. METHODS : Twelve potential clinical niches identified by clinical experts were evaluated based on a comprehensive, non-systematic review of literature published to date. Relevant publications were identified by targeted literature searches of EMBASE and PubMed using key search terms specific to each niche. Articles published in English or other European languages up to 2016 were included. FINDINGS : Several niches were found to be relevant based on available data: movement disorders (early-onset ataxia and dystonia), organic psychosis, early-onset cholestasis/(hepato)splenomegaly, cases with relevant antenatal findings or fetal abnormalities, and patients affected by family history, consanguinity, and endogamy. Potentially relevant niches requiring further supportive data included: early-onset cognitive decline, frontotemporal dementia, parkinsonism, and chronic inflammatory CNS disease. There was relatively weak evidence to suggest amyotrophic lateral sclerosis or progressive supranuclear gaze palsy as potential niches. CONCLUSIONS : Several clinical niches have been identified that harbor patients at increased risk of NP-C. | en_ZA |
| dc.description.department | Paediatrics and Child Health | en_ZA |
| dc.description.embargo | 2018-03-02 | |
| dc.description.librarian | hj2018 | en_ZA |
| dc.description.sponsorship | Actelion Pharmaceuticals Ltd., Allschwil, Switzerland. From Actelion Pharmaceuticals Ltd.: travel expenses AC, AD, AP, CD-V, CJH, CL, HHK, MT, MW, MP, MS, PB, OB, SD, SL; research funding AP, CL, CD-V, CJH, FT-B, J-CC, MW, OB, PB, RI, SD, TD, TdK; consultancy fees AP, CJH, CL, HHK, MT, MW, OB, PB, SL; speaker honoraria CD-V, MP, MS, PB, SD. MA has received speaker honoraria and travel expenses from Abbvie, TEVA, and UCB. J-CC has received speaker honoraria from Abbvie, travel grants from Abbvie, research funding from, Ipsen, and the Michael J Fox Foundation, and consultancy fees from BMS, Zambon, Pfizer, Amarantus, Clevexel, and Abbvie. CD-V has received research grants, investigator fees, speaker honoraria, and travel expenses from Sanofi Genzyme, Orphan Europe, and Nutricia. SD has received research funding from TEVA. CJH is Director of FYMCA Medical Ltd., has received consultancy fees and travel expenses from Alexion, Amicus, Biomarin, Inventiva, Sanofi Genzyme, and Shire, and has undertaken paid research on behalf of Amicus, Biomarin, Sanofi Genzyme and Shire. SL has received consultancy fees and travel expenses from TEVA, Boehringer, Gruenenthal, and UCB6e. AP has received research funding, consultancy fees and travel expenses from Eli-Lilly, GE Health, and Lundbeck. CT has received speaker honoraria and travel expenses from Abbvie, Zambon, TEVA, and UCB. CV and SK are employees of Actelion Pharmaceuticals Ltd. | en_ZA |
| dc.description.uri | http://www.tandfonline.com/loi/icmo20 | en_ZA |
| dc.identifier.citation | Christian J. Hendriksz, Mathieu Anheim, Peter Bauer, Olivier Bonnot, Anupam Chakrapani, Jean-Christophe Corvol, Tom J. de Koning, Anna Degtyareva, Carlo Dionisi-Vici, Sarah Doss, Thomas Duning, Paola Giunti, Rosa Iodice, Tracy Johnston, Dierdre Kelly, Hans- Hermann Kl ünemann, Stefan Lorenzl, Alessandro Padovani, Miguel Pocovi, Matthis Synofzik, Alta Terblanche, Florian Then Bergh, Meral Top çu, Christine Tranchant, Mark Walterfang, Christian Velten & Stefan A. Kolb (2017) The hidden Niemann-Pick type C patient: clinical niches for a rare inherited metabolic disease, Current Medical Research and Opinion, 33:5, 877-890, DOI: 10.1080/03007995.2017.1294054. | en_ZA |
| dc.identifier.issn | 0300-7995 (print) | |
| dc.identifier.issn | 1473-4877 (online) | |
| dc.identifier.issn | 10.1080/03007995.2017.1294054 | |
| dc.identifier.uri | http://hdl.handle.net/2263/64137 | |
| dc.language.iso | en | en_ZA |
| dc.publisher | Taylor and Francis | en_ZA |
| dc.rights | © 2017 Informa UK Limited, trading as Taylor & Francis Group. This is an electronic version of an article published in Current Medical Research and Opinion, vol. 33, no. 5, pp. 877-890, 2017. doi : 10.1080/03007995.2017.1294054. Current Medical Research and Opinion is available online at :http://www.tandfonline.com/loi/icmo20. | en_ZA |
| dc.subject | Niemann-Pick disease type C (NP-C) | en_ZA |
| dc.subject | Diagnosis | en_ZA |
| dc.subject | Screening | en_ZA |
| dc.subject | Clinical niche | en_ZA |
| dc.subject | Differential diagnosis | en_ZA |
| dc.subject | Epidemiology | en_ZA |
| dc.subject | Inborn errors of metabolism (IEM) | en_ZA |
| dc.subject | Early-onset ataxia (EOA) | en_ZA |
| dc.subject | Schizophrenia | en_ZA |
| dc.subject | Multiple sclerosis (MS) | en_ZA |
| dc.subject | Genotype-phenotype correlations | en_ZA |
| dc.subject | Hexanucleotide repeat expansion | en_ZA |
| dc.subject | Frontotemporal lobar degeneration-tau (FTLD-tau) | en_ZA |
| dc.subject | Amyotrophic lateral sclerosis | en_ZA |
| dc.subject | Progressive supranuclear gaze palsy (PSP) | en_ZA |
| dc.title | The hidden Niemann-Pick type C patient : clinical niches for a rare inherited metabolic disease | en_ZA |
| dc.type | Postprint Article | en_ZA |
